-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

1981 Integration of Hi-C and Nanopore Sequencing for Structural Variant Analysis in AML with a Complex Karyotype: (Chromothripsis)²

Program: Oral and Poster Abstracts
Session: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster II
Hematology Disease Topics & Pathways:
AML, Adult, Diseases, Biological Processes, Technology and Procedures, Study Population, genomics, Myeloid Malignancies, integrative -omics, RNA sequencing, WGS
Sunday, December 6, 2020, 7:00 AM-3:30 PM

Marius-Konstantin Klever1,2,3*, Eric Sträng, PhD2*, Julius Jungnitsch3,4*, Uirá Souto Melo1,3*, Sara Hetzel5*, Anna Dolnik2*, Robert Schöpflin1,3*, Jens F. Schrezenmeier2*, Olga Blau2,6, Jörg Westermann7*, Konstanze Dohner, MD8, Hubert Schrezenmeier9,10, Malte Spielmann4,11*, Alexander Meissner, PhD12*, Stefan Mundlos1,3,6* and Lars Bullinger, MD2,6

1RG Development and Disease, Max Planck Institute for Molecular Genetics, Berlin, Germany
2Department of Hematology, Oncology and Tumor Immunology, Charité University Medicine Berlin, Berlin, Germany
3Institute for Medical Genetics and Human Genetics, Charité University Medicine Berlin, Berlin, Germany
4Human Molecular Genomics Group, Max Planck Institute for Molecular Genetics, Berlin, Germany
5Department of Genome Regulation, Max Planck Institute For Molecular Genetics, Berlin, Germany
6Labor Berlin – Charité Vivantes GmbH, Berlin, Germany
7Department of Hematology, Oncology and Tumor Immunology, Charite-Universitaetsmedizin Berlin, Berlin, Germany
8Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany
9Institute of Transfusion Medicine, University of Ulm, Ulm, Germany, and Institute for Clinical Transfusion Medicine and Immunogenetics, German Red Cross Blood Transfusion Service Baden-Württemberg-Hessen, and University Hospital Ulm, Ulm, Germany
10Institute for Clinical Transfusion Medicine and Immunogenetics, German Red Cross Blood Transfusion Service Baden-Württemberg-Hessen and University Hospital Ulm, Ulm, Germany
11Institut für Humangenetik Lübeck, Universität zu Lübeck, Lübeck, Germany
12Department of Genome Regulation, Max Planck Institute for Molecular Genetics, Berlin, Germany

Background. Acute myeloid leukemia (AML) with a complex karyotype (CK-AML) is an AML subtype with a still dismal outcome despite recent therapeutic advances. The prognosis is even worse when the underlying structural variants (SVs) lead to an extremely complex pattern of rearrangements, called chromothripsis, with a median overall survival of only 120 days. Except for the presence of inactivating TP53 aberrations in about 70% of all AML-CK cases, the pathogenesis is poorly understood. To gain novel insights into the molecular mechanisms underlying CK-AML reliable high precision SV delineation is needed, which so far has been a major limitation in cancer research.

Aim. We developed a SV detection pipeline by integrating Oxford Nanopore Technology (ONT) based whole genome sequencing (WGS) and Hi-C sequencing. This pipeline generated precise characterization of SVs for which the impact on gene expression and the emergence of novel fusion genes was studied by RNA-seq and ONT transcriptome sequencing.

Patients and Methods. We applied our WGS and Hi-C SV detection pipeline to a cohort of 11 AML-CK cases. Nanopore DNA Sequencing was performed until a genomic coverage >10x per patient was reached. The samples of 9 patients were also subjected to Nanopore cDNA sequencing for fusion gene analysis and Illumina based RNA-seq for transcript quantification. As controls for Hi-C and Illumina RNA sequencing, CD34+ hematopoietic stem cell enriched samples from five healthy donors were used.

Results. Our SV detection pipeline enabled us to fully reconstruct the derivate chromosome structure even of very complex, chromothriptic rearrangements in CK-AML. This enabled us to identify features of chromothripsis, that could previously not be detected using conventual technologies. We found local clustering of breakpoints in three of the patients with up to 31 Inversions and Translocations located in a genomic region of just 2.7 kb. These breakpoints were present in the Hi-C as well as in our Nanopore SV dataset. Our SV pipeline also showed that in these highly clustered regions, the very small rejoined fragments (in many cases less than 1 kb in size) often showed an elevated copy number (CN) state, i.e. small amplifications. We termed this newly discovered phenomenon chromothripsis-in-chromothripsis or (chromothripsis)². The precise knowledge about these breakpoints, which were validated by two different technologies, enabled us to study the pathogenesis of CK-AML at a so far unprecedented resolution. Fusion transcripts could be very precisely mapped and the impact of the breakpoints and CN changes on gene expression levels could be validated, thereby indicating functional relevance of the respective aberrations.

Conclusions. The combination of Hi-C and long-read sequencing for SV detection proved to be a powerful tool for precise SV detection. Our SV pipeline allowed us to discover a new level of complexity in chromothripsis. Application of this pipeline to leukemias as well as other types of cancer can improve the precision of SV detection, thereby raising new opportunities for functional interpretation of complex genomic aberrations of pathogenic relevance.

Disclosures: Dohner: Celgene: Consultancy, Honoraria; Astellas Pharma: Consultancy; Daiichi Sankyo: Honoraria; Abbvie: Consultancy; Agios: Consultancy; Amgen: Consultancy, Research Funding; Janssen: Consultancy, Honoraria; Pfizer: Research Funding; Bristol-Myers Squibb: Research Funding; Arog: Research Funding; Astex Pharmaceuticals: Consultancy; Novartis: Honoraria, Research Funding; Jazz Pharmaceuticals: Consultancy, Honoraria, Research Funding; Roche: Consultancy; Sunesis Pharmaceuticals: Research Funding. Schrezenmeier: Alexion Pharmaceuticals Inc.: Honoraria, Research Funding. Bullinger: Amgen: Membership on an entity's Board of Directors or advisory committees; Astellas: Membership on an entity's Board of Directors or advisory committees; Bristol-Myers Squibb: Membership on an entity's Board of Directors or advisory committees; Celgene: Membership on an entity's Board of Directors or advisory committees; Seattle Genetics: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees; Jazz Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees; Pfizer: Membership on an entity's Board of Directors or advisory committees; Hexal: Membership on an entity's Board of Directors or advisory committees; Gilead: Membership on an entity's Board of Directors or advisory committees; Daiichi Sankyo: Membership on an entity's Board of Directors or advisory committees; Abbvie: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees; Sanofi: Membership on an entity's Board of Directors or advisory committees; Menarini: Membership on an entity's Board of Directors or advisory committees.

*signifies non-member of ASH